Molecular Insights into EGFR Inhibition by Lapatinib and Emerging HER2 Mutant Kinase Inhibitors

Abstract The epidermal growth factor receptor (EGFR) plays a central role in the progression of multiple cancers, and resistance to tyrosine kinase inhibitors remains a significant therapeutic challenge. In this study, we employ an integrated computational approach combining molecular docking, all-atom molecular dynamics simulations, and the advanced funnel metadynamics (FM) method to investigate the binding mechanisms of the experimentally supported lapatinib-EGFR system and the potential binding behavior of recently approved HER2 mutant inhibitors zongertinib and sevabertinib toward the EGFR kinase domain. Lapatinib exhibits structural stability of the EGFR kinase domain throughout the simulation. The modeled HER2 mutant kinase inhibitors-EGFR complexes also exhibited stable conformations of the kinase domain. Residue-level interaction and binding mode analysis demonstrate that all inhibitors occupy the canonical binding groove and engage key active-site residues. The relative residence times for lapatinib (1.72 ± 0.14 ns) and zongertinib (1.87 ± 0.16 ns) obtained through τRAMD suggest comparable accelerated dissociation times. In contrast, sevabertinib showed a substantially shorter residence time (0.17 ± 0.01 ns), indicating a faster dissociation process and weaker retention within the kinase binding pocket. The absolute binding free energy of lapatinib (−13.7 ± 0.5 kcal mol–1) obtained from FM is in reasonable agreement with the experimental value. Moreover, the binding free energies of zongertinib (−20.0 ± 0.6 kcal mol–1) and sevabertinib (−9.2 ± 0.8 kcal mol–1) follow trends consistent with their relative residence times. Overall, the combined structural and binding-mode analyses suggest that zongertinib may adopt a favorable binding mode within the modeled EGFR complex. These findings provide a computational hypothesis for the potential interaction of zongertinib with EGFR, which requires further experimental validation.

Authors

Institutions

Publication Details

Journal
The Journal of Physical Chemistry B
Published
2026-11-16
DOI
https://doi.org/10.1021/acs.jpcb.6c03843
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Molecular Insights into EGFR Inhibition by Lapatinib and Emerging HER2 Mutant Kinase Inhibitors

Atanu K. Metya, Karnati Ganesh Reddy
The Journal of Physical Chemistry B
Computational Drug Discovery Methods
article

Molecular Insights into EGFR Inhibition by Lapatinib and Emerging HER2 Mutant Kinase Inhibitors

Atanu K. Metya, Karnati Ganesh Reddy
article en

Abstract

Abstract The epidermal growth factor receptor (EGFR) plays a central role in the progression of multiple cancers, and resistance to tyrosine kinase inhibitors remains a significant therapeutic challenge. In this study, we employ an integrated computational approach combining molecular docking, all-atom molecular dynamics simulations, and the advanced funnel metadynamics (FM) method to investigate the binding mechanisms of the experimentally supported lapatinib-EGFR system and the potential binding behavior of recently approved HER2 mutant inhibitors zongertinib and sevabertinib toward the EGFR kinase domain. Lapatinib exhibits structural stability of the EGFR kinase domain throughout the simulation. The modeled HER2 mutant kinase inhibitors-EGFR complexes also exhibited stable conformations of the kinase domain. Residue-level interaction and binding mode analysis demonstrate that all inhibitors occupy the canonical binding groove and engage key active-site residues. The relative residence times for lapatinib (1.72 ± 0.14 ns) and zongertinib (1.87 ± 0.16 ns) obtained through τRAMD suggest comparable accelerated dissociation times. In contrast, sevabertinib showed a substantially shorter residence time (0.17 ± 0.01 ns), indicating a faster dissociation process and weaker retention within the kinase binding pocket. The absolute binding free energy of lapatinib (−13.7 ± 0.5 kcal mol–1) obtained from FM is in reasonable agreement with the experimental value. Moreover, the binding free energies of zongertinib (−20.0 ± 0.6 kcal mol–1) and sevabertinib (−9.2 ± 0.8 kcal mol–1) follow trends consistent with their relative residence times. Overall, the combined structural and binding-mode analyses suggest that zongertinib may adopt a favorable binding mode within the modeled EGFR complex. These findings provide a computational hypothesis for the potential interaction of zongertinib with EGFR, which requires further experimental validation.

The Journal of Physical Chemistry B
Indian Institute of Technology Patna (IN)
Ministry of Education, India
Good health and well-being
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon